Eli Lilly insulin (various forms)

Eli Lilly insulin (various forms) - supply shortage

Medicine Shortage Communication (MSC): Insulin (human insulin) (various short-, rapid-, intermediate-, mixed- and long-acting forms) 2026

Good Manufacturing Practice (GMP) / Good Distribution Practice (GDP) Inspectors Working Group

Human medicines European public assessment report (EPAR): Shingrix, herpes zoster vaccine (recombinant, adjuvanted), Date of authorisation: 21/03/2018, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Sondelbay, teriparatide, Date of authorisation: 24/03/2022, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Vaborem, meropenem,vaborbactam, Date of authorisation: 20/11/2018, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Tremfya, guselkumab, Date of authorisation: 10/11/2017, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Waylivra, volanesorsen, Date of authorisation: 03/05/2019, Revision: 8, Status: Authorised

Outcome of written procedures finalised during the period from 4 December 2025 to 3 March 2026